Showing results (211-220 of 397) with videos related to
Sort By:
Pageof 40
Journal of Cancer Research and Clinical Oncology|February 24, 2001
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignanciesM Markman, A Kennedy, K Webster, et al.Gynecologic Oncology|March 1, 1996
Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasoneM Markman, A Kennedy, K Webster, et al.Seminars in Oncology|June 1, 1996
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitisM Markman, A Kennedy, K Webster, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot StudyP Francis, E Rowinsky, J Schneider, et al.Journal of Cancer Research and Clinical Oncology|August 6, 1998
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinomaM Markman, A Kennedy, K Webster, et al.Gynecologic Oncology|June 15, 1999
Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancerM Markman, A Kennedy, K Webster, et al.Journal of Cancer Research and Clinical Oncology|May 18, 2000
Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropeniaM Markman, A Kennedy, K Webster, et al.Gynecologic Oncology|September 28, 2000
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancerM Markman, A Kennedy, K Webster, et al.Gynecologic Oncology|September 14, 2000
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneumM Markman, A Kennedy, K Webster, et al.Gynecologic Oncology|April 29, 2000
Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant resultsM Markman, A Kennedy, K Webster, et al.Pageof 40